1 Study Coverage 1.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Introduction 1.2 Market by Type 1.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 1g/20ml 1.2.3 1.25g/25ml 1.2.4 2.5g/50ml 1.2.5 5g/100ml 1.2.6 10g/200ml 1.3 Market by Application 1.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Estimates and Forecasts 2017-2028 2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Estimates and Forecasts 2017-2028 2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region 2.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) 2.4.2 Global Sales Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2023-2028) 2.5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region 2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) 2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers 3.1.1 Global Top Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers by Sales (2017-2022) 3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in 2021 3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers 3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022) 3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021 3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type 4.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Type (2017-2022) 4.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Type (2023-2028) 4.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) 4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type 4.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Type (2017-2022) 4.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Type (2023-2028) 4.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) 4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type 4.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022) 4.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028) 5 Market Size by Application 5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application 5.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Application (2017-2022) 5.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Application (2023-2028) 5.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) 5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application 5.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Application (2017-2022) 5.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Application (2023-2028) 5.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) 5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application 5.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022) 5.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028) 6 North America 6.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type 6.1.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028) 6.1.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028) 6.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application 6.2.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028) 6.2.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028) 6.3 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country 6.3.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028) 6.3.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type 7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028) 7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028) 7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application 7.2.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028) 7.2.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028) 7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country 7.3.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028) 7.3.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type 8.1.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028) 8.1.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028) 8.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application 8.2.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028) 8.2.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028) 8.3 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region 8.3.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2028) 8.3.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 8.3.12 Philippines 9 Latin America 9.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type 9.1.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028) 9.1.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028) 9.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application 9.2.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028) 9.2.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028) 9.3 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country 9.3.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028) 9.3.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type 10.1.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028) 10.1.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028) 10.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application 10.2.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028) 10.2.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028) 10.3 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country 10.3.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028) 10.3.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia 11 Company Profiles 11.1 Boya-Bio 11.1.1 Boya-Bio Corporation Information 11.1.2 Boya-Bio Overview 11.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Boya-Bio Recent Developments 11.2 Beijing Tiantan Biological Products 11.2.1 Beijing Tiantan Biological Products Corporation Information 11.2.2 Beijing Tiantan Biological Products Overview 11.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 Beijing Tiantan Biological Products Recent Developments 11.3 Hualan Bio 11.3.1 Hualan Bio Corporation Information 11.3.2 Hualan Bio Overview 11.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.3.4 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.3.5 Hualan Bio Recent Developments 11.4 Guangdong Shuagnlin Bio-pharmacy 11.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information 11.4.2 Guangdong Shuagnlin Bio-pharmacy Overview 11.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.4.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments 11.5 Weiguang Biological 11.5.1 Weiguang Biological Corporation Information 11.5.2 Weiguang Biological Overview 11.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.5.4 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.5.5 Weiguang Biological Recent Developments 11.6 Sinopharm 11.6.1 Sinopharm Corporation Information 11.6.2 Sinopharm Overview 11.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.6.4 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.6.5 Sinopharm Recent Developments 11.7 Shanghai RAAS 11.7.1 Shanghai RAAS Corporation Information 11.7.2 Shanghai RAAS Overview 11.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.7.4 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.7.5 Shanghai RAAS Recent Developments 11.8 CTBB 11.8.1 CTBB Corporation Information 11.8.2 CTBB Overview 11.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.8.4 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.8.5 CTBB Recent Developments 11.9 Nanyue Biopharming 11.9.1 Nanyue Biopharming Corporation Information 11.9.2 Nanyue Biopharming Overview 11.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022) 11.9.4 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications 11.9.5 Nanyue Biopharming Recent Developments 12 Industry Chain and Sales Channels Analysis 12.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Chain Analysis 12.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Mode & Process 12.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Marketing 12.4.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Channels 12.4.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors 12.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Trends 13.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers 13.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges 13.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints 14 Key Findings in The Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer

List of Tables Table 1. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of 1g/20ml Table 3. Major Manufacturers of 1.25g/25ml Table 4. Major Manufacturers of 2.5g/50ml Table 5. Major Manufacturers of 5g/100ml Table 6. Major Manufacturers of 10g/200ml Table 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million) Table 9. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units) Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022) Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units) Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2023-2028) Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million) Table 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2017-2022) Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million) Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2023-2028) Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers (2017-2022) & (K Units) Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers (2017-2022) Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022) & (US$ Million) Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2017-2022) Table 21. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Manufacturers (2017-2022) &(US$/Unit) Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Market Concentration Ratio (CR5 and HHI) Table 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) as of 2021) Table 24. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution and Headquarters Table 25. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered Table 26. Date of Manufacturers Enter into Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2017-2022) Table 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2023-2028) Table 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2017-2022) Table 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2023-2028) Table 36. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022) & (US$/Unit) Table 37. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028) & (US$/Unit) Table 38. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 39. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 40. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2017-2022) Table 41. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2023-2028) Table 42. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 43. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 44. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2017-2022) Table 45. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2023-2028) Table 46. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022) & (US$/Unit) Table 47. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028) & (US$/Unit) Table 48. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 49. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 50. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 51. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 52. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 53. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 54. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 55. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 56. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units) Table 57. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units) Table 58. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million) Table 59. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million) Table 60. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 61. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 62. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 63. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 64. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 65. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 66. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 67. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 68. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units) Table 69. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units) Table 70. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million) Table 71. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million) Table 72. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 73. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 74. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 75. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 76. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 77. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 78. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 79. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 80. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units) Table 81. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units) Table 82. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million) Table 83. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million) Table 84. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 85. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 86. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 87. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 88. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 89. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 90. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 91. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 92. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units) Table 93. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units) Table 94. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million) Table 95. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million) Table 96. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units) Table 97. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units) Table 98. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million) Table 99. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million) Table 100. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units) Table 101. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units) Table 102. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million) Table 103. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million) Table 104. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units) Table 105. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units) Table 106. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million) Table 107. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million) Table 108. Boya-Bio Corporation Information Table 109. Boya-Bio Description and Major Businesses Table 110. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 111. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 112. Boya-Bio Recent Developments Table 113. Beijing Tiantan Biological Products Corporation Information Table 114. Beijing Tiantan Biological Products Description and Major Businesses Table 115. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 116. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 117. Beijing Tiantan Biological Products Recent Developments Table 118. Hualan Bio Corporation Information Table 119. Hualan Bio Description and Major Businesses Table 120. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 121. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 122. Hualan Bio Recent Developments Table 123. Guangdong Shuagnlin Bio-pharmacy Corporation Information Table 124. Guangdong Shuagnlin Bio-pharmacy Description and Major Businesses Table 125. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 126. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 127. Guangdong Shuagnlin Bio-pharmacy Recent Developments Table 128. Weiguang Biological Corporation Information Table 129. Weiguang Biological Description and Major Businesses Table 130. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 131. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 132. Weiguang Biological Recent Developments Table 133. Sinopharm Corporation Information Table 134. Sinopharm Description and Major Businesses Table 135. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 136. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 137. Sinopharm Recent Developments Table 138. Shanghai RAAS Corporation Information Table 139. Shanghai RAAS Description and Major Businesses Table 140. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 141. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 142. Shanghai RAAS Recent Developments Table 143. CTBB Corporation Information Table 144. CTBB Description and Major Businesses Table 145. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 146. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 147. CTBB Recent Developments Table 148. Nanyue Biopharming Corporation Information Table 149. Nanyue Biopharming Description and Major Businesses Table 150. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 151. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications Table 152. Nanyue Biopharming Recent Developments Table 153. Key Raw Materials Lists Table 154. Raw Materials Key Suppliers Lists Table 155. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List Table 156. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers List Table 157. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Trends Table 158. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers Table 159. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges Table 160. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints Table 161. Research Programs/Design for This Report Table 162. Key Data Information from Secondary Sources Table 163. Key Data Information from Primary Sources List of Figures Figure 1. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Picture Figure 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Type in 2021 & 2028 Figure 3. 1g/20ml Product Picture Figure 4. 1.25g/25ml Product Picture Figure 5. 2.5g/50ml Product Picture Figure 6. 5g/100ml Product Picture Figure 7. 10g/200ml Product Picture Figure 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Application in 2021 & 2028 Figure 9. Hospital Figure 10. Clinic Figure 11. Others Figure 12. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Report Years Considered Figure 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2028 (K Units) Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2028 (US$ Million) Figure 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region in Percentage: 2021 Versus 2028 Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022) Figure 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2023-2028) Figure 19. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units) Figure 20. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million) Figure 21. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units) Figure 22. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million) Figure 23. Asia-Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units) Figure 24. Asia-Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million) Figure 25. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units) Figure 26. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million) Figure 27. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units) Figure 28. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million) Figure 29. The Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021 Figure 30. The Top 5 and 10 Largest Manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in the World: Market Share by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021 Figure 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021 Figure 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 36. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 37. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 38. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 39. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 40. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028) Figure 41. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028) Figure 42. U.S. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 43. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 44. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 45. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 46. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 47. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 48. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028) Figure 49. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028) Figure 50. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 51. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 52. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 53. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 54. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 55. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 56. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 57. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 58. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 59. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Region (2017-2028) Figure 60. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Region (2017-2028) Figure 61. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 62. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 63. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 64. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 65. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 66. Taiwan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 67. Indonesia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 68. Thailand Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 69. Malaysia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 70. Philippines Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 71. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 72. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 73. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 74. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 75. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028) Figure 76. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028) Figure 77. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 78. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 79. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 80. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028) Figure 81. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028) Figure 82. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028) Figure 83. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028) Figure 84. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028) Figure 85. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028) Figure 86. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 87. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 88. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million) Figure 89. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Chain Figure 90. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Process Figure 91. Channels of Distribution Figure 92. Distributors Profiles Figure 93. Bottom-up and Top-down Approaches for This Report Figure 94. Data Triangulation Figure 95. Key Executives Interviewed

Boya-Bio Beijing Tiantan Biological Products Hualan Bio Guangdong Shuagnlin Bio-pharmacy Weiguang Biological Sinopharm Shanghai RAAS CTBB Nanyue Biopharming